FDA grants conditional approval to Sarepta’s gene therapy for Duchenne muscular dystrophy
The Food and Drug Administration granted conditional approval Thursday to the first gene therapy for Duchenne muscular dystrophy. Regulators restricted the treatment to younger patients, with additional data required to broaden its use.
The gene therapy, called Elevydis, is made by Sarepta Therapeutics.
